Why explore GLP‑1 agonists for AUD

In this episode, we explore a surprising new contender in the fight against alcohol use disorder — semaglutide. Could the blockbuster weight-loss drug also curb heavy drinking? We examine the first randomized controlled trial testing this GLP-1 receptor agonist specifically for AUD.

Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CMEs: Quick Take Vol. 79
• Semaglutide for Alcohol Use Disorder: New RCT Data